Carole Déan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carole Déan has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Marc Sapoval
Department of Vascular and Oncological Interventional Radiology, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, 75015 Paris, France; Université Paris Cité, Inria, Inserm, HeKA, PR[AI]RIE-PSAI, 75015 Paris, France
10 shared publications - Olivier Pellerin
Service de Radiologie Interventionnelle, Université de Paris, France
9 shared publications - Helena Pereira
CIC-EC4 URC HEGP, Hôpitaux Universitaires Paris Ouest (AP-HP), Paris, France
5 shared publications - Tom Boeken
Inria, Université Paris Cité, Inserm, HeKA
5 shared publications - Costantino Del Giudice
Department of Radiology, Interventional Radiology, Institut Mutualiste Montsouris, Paris, France
4 shared publications Marc Sapoval
Assistance Publique - Hôpitaux de Paris, Hôpital Européen Georges Pompidou Vascular and Oncological Interventional Radiology Department, 75015 Paris, France; Université Paris Cité, 75006 Paris, France
4 shared publications
Latest Publications
- Open Access
- 1 January 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 37, 100821
Decoding the complexity of benign prostatic hyperplasia therapies in the PARTEM trial—authors’ reply
- 1 January 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 37, 100821
Open AccessDecoding the complexity of benign prostatic hyperplasia therapies in the PARTEM trial—authors’ reply
- Open Access
- 14 December 2023
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 105 (4) , 144-150
Genicular artery embolization for knee osteoarthritis: Results of the LipioJoint-1 trial
- 14 December 2023
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 105 (4) , 144-150
Open AccessGenicular artery embolization for knee osteoarthritis: Results of the LipioJoint-1 trial
- 26 October 2023
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 47 (2) , 283-284
How Artificial Intelligence will Reshape our Interventional Units
- 26 October 2023
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 47 (2) , 283-284
How Artificial Intelligence will Reshape our Interventional Units
- Open Access
Exploring a Novel Technique to Tackle the Shortage of Devices for Hepatic Arterial Infusion Chemotherapy: Early Results of an Alternate Approach for Percutaneous Arterial Port Catheter Placement
Dedicated catheters for hepatic arterial infusion chemotherapy were removed from the market. The purpose of this study was to assess the results of a novel approach to overcome the shortage of dedicated catheters for hepatic arterial infusion chemotherapy in the treatment of colorectal cancer liver metastases. We retrospectively included patients who underwent a percutaneous placement of a hepatic intra-arterial port catheter in a single tertiary center from February 2021 to June 2022. We examined the patient baseline characteristics, technical features of the modified procedures, technical success rates, complications and oncological outcomes. Fourteen patients (median age: 60 years; q1 = 54; q3 = 70; range: 53–81 years) underwent 15 modified procedures. The main modification of our placement technique consisted of the use of an indwelling 5-Fr Vertebral catheter, on the tip of which we created a two-sided additional lateral hole. The catheter was connected to a pediatric port. The primary success rate was 100%, and the secondary success rate was 93.3%. There were two late major complications, graded IIIa according to the Clavien–Dindo classification. The median liver progression free survival was 6.1 months (q1 = 2.5; q3 = 7.2; range: 1.3–11.6). Our experience suggests that the derived utilization of the devices used routinely in interventional radiology provides an effective solution that can compensate for the shortage of dedicated devices.
Open AccessExploring a Novel Technique to Tackle the Shortage of Devices for Hepatic Arterial Infusion Chemotherapy: Early Results of an Alternate Approach for Percutaneous Arterial Port Catheter Placement
Dedicated catheters for hepatic arterial infusion chemotherapy were removed from the market. The purpose of this study was to assess the results of a novel approach to overcome the shortage of dedicated catheters for hepatic arterial infusion chemotherapy in the treatment of colorectal cancer liver metastases. We retrospectively included patients who underwent a percutaneous placement of a hepatic intra-arterial port catheter in a single tertiary center from February 2021 to June 2022. We examined the patient baseline characteristics, technical features of the modified procedures, technical success rates, complications and oncological outcomes. Fourteen patients (median age: 60 years; q1 = 54; q3 = 70; range: 53–81 years) underwent 15 modified procedures. The main modification of our placement technique consisted of the use of an indwelling 5-Fr Vertebral catheter, on the tip of which we created a two-sided additional lateral hole. The catheter was connected to a pediatric port. The primary success rate was 100%, and the secondary success rate was 93.3%. There were two late major complications, graded IIIa according to the Clavien–Dindo classification. The median liver progression free survival was 6.1 months (q1 = 2.5; q3 = 7.2; range: 1.3–11.6). Our experience suggests that the derived utilization of the devices used routinely in interventional radiology provides an effective solution that can compensate for the shortage of dedicated devices.
- Open Access
- 26 June 2023
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 31, 100672
Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial
- 26 June 2023
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 31, 100672
Open AccessProstatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial
- 16 February 2023
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 104 (6) , 292-296
Long-term outcomes of prostate artery embolization for acute urinary retention: An analysis of 88 patients
- 16 February 2023
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 104 (6) , 292-296
Long-term outcomes of prostate artery embolization for acute urinary retention: An analysis of 88 patients
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Prostatic Artery Embolisation Versus Medical Treatment in Patients with Benign Prostatic Hyperplasia (PARTEM): A Randomised, Multicentre, Open-Label, Phase 3, Superiority Trial
Background: Prostatic artery embolisation (PAE) is a minimally invasive treatment of symptomatic benign prostatic hyperplasia (BPH). Our aim was to compare patient’s symptoms improvement after PAE and medical treatment. Methods: A randomised, open-label, superiority trial was set in 10 French hospitals. Patients with bothersome lower urinary tract symptoms (LUTS) related to BPH ≥50 ml resistant to alpha-blocker monotherapy were randomly assigned (1:1) to PAE or Combined Therapy ([CT], oral dutasteride 0·5 mg / tamsulosin hydrochloride 0·4 mg per day). Randomisation was stratified by centre, International Prostatic Symptom Score (IPSS) and prostate volume with a minimisation procedure to ensure balanced allocation. The primary outcome was the 9-month change in IPSS. Primary and safety analysis were done according to the intention-to-treat (ITT) principle among patients with an evaluable primary outcome (modified ITT). ClinicalTrials.gov Identifier: NCT02869971. Findings: Ninety patients were randomised from September 2016 to February 2020, and 44 and 43 patients assessed for primary endpoint in PAE and CT groups respectively. The 9-month change of IPSS was -10·0 (95% confidence interval [CI]: -11·8 to -8·3) and -5·7 (95% CI: -7·5 to -3·8) in the PAE and CT groups, respectively. This reduction was significantly greater in the PAE group than in the CT group (-4·4 [95% CI: -6·9 to -1·9], P=0·0008). The IIEF-15 score change was 8·2 (95% CI: 2·9 to 13·5) and -2·8 (95% CI: -8·4 to 2·8) in the PAE and CT groups, respectively. No treatment-related AE or hospitalisation was noticed. After 24 months, 5 and 18 patients had invasive prostate re-treatment in the PAE and CT group respectively. Interpretation: In patients with BPH ≥50 ml and bothersome LUTS resistant to alpha-blocker monotherapy, PAE provides more urinary and sexual symptoms score benefit than CT up to 24 months. Trial Registration Details: This study was registered with ClinicalTrials.gov Identifier: NCT02869971. Funding Information: The trial was sponsored by Assistance Publique - Hôpitaux de Paris and funded by a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique) and supplemented with a research grant from Merit Medical. Declaration of Interests: NT, AD, CD, AR, GP, RCD, GR, FP, GK, VV, TM, HVK, ADLT, HK, RM, JFH, SD, JF, NBD, VKS, IDZ, HP, CD, and GC declare no conflict of interest. MS reports consulting fees from Merit medical. Ethics Approval Statement: The trial protocol was approved by an ethics committee (Comité de Protection des Personnes Ile de France VII). All participants provided written informed consent. conducted following the principles of the Declaration of Helsinki, Clinical Practice guidelines, and local guidelines.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessProstatic Artery Embolisation Versus Medical Treatment in Patients with Benign Prostatic Hyperplasia (PARTEM): A Randomised, Multicentre, Open-Label, Phase 3, Superiority Trial
Background: Prostatic artery embolisation (PAE) is a minimally invasive treatment of symptomatic benign prostatic hyperplasia (BPH). Our aim was to compare patient’s symptoms improvement after PAE and medical treatment. Methods: A randomised, open-label, superiority trial was set in 10 French hospitals. Patients with bothersome lower urinary tract symptoms (LUTS) related to BPH ≥50 ml resistant to alpha-blocker monotherapy were randomly assigned (1:1) to PAE or Combined Therapy ([CT], oral dutasteride 0·5 mg / tamsulosin hydrochloride 0·4 mg per day). Randomisation was stratified by centre, International Prostatic Symptom Score (IPSS) and prostate volume with a minimisation procedure to ensure balanced allocation. The primary outcome was the 9-month change in IPSS. Primary and safety analysis were done according to the intention-to-treat (ITT) principle among patients with an evaluable primary outcome (modified ITT). ClinicalTrials.gov Identifier: NCT02869971. Findings: Ninety patients were randomised from September 2016 to February 2020, and 44 and 43 patients assessed for primary endpoint in PAE and CT groups respectively. The 9-month change of IPSS was -10·0 (95% confidence interval [CI]: -11·8 to -8·3) and -5·7 (95% CI: -7·5 to -3·8) in the PAE and CT groups, respectively. This reduction was significantly greater in the PAE group than in the CT group (-4·4 [95% CI: -6·9 to -1·9], P=0·0008). The IIEF-15 score change was 8·2 (95% CI: 2·9 to 13·5) and -2·8 (95% CI: -8·4 to 2·8) in the PAE and CT groups, respectively. No treatment-related AE or hospitalisation was noticed. After 24 months, 5 and 18 patients had invasive prostate re-treatment in the PAE and CT group respectively. Interpretation: In patients with BPH ≥50 ml and bothersome LUTS resistant to alpha-blocker monotherapy, PAE provides more urinary and sexual symptoms score benefit than CT up to 24 months. Trial Registration Details: This study was registered with ClinicalTrials.gov Identifier: NCT02869971. Funding Information: The trial was sponsored by Assistance Publique - Hôpitaux de Paris and funded by a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique) and supplemented with a research grant from Merit Medical. Declaration of Interests: NT, AD, CD, AR, GP, RCD, GR, FP, GK, VV, TM, HVK, ADLT, HK, RM, JFH, SD, JF, NBD, VKS, IDZ, HP, CD, and GC declare no conflict of interest. MS reports consulting fees from Merit medical. Ethics Approval Statement: The trial protocol was approved by an ethics committee (Comité de Protection des Personnes Ile de France VII). All participants provided written informed consent. conducted following the principles of the Declaration of Helsinki, Clinical Practice guidelines, and local guidelines.
- 1 December 2021
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 102 (12) , 709-715
Prostate artery chemoembolization in prostate cancer: A proof of concept study in spontaneous prostate cancer in a canine model
- 1 December 2021
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 102 (12) , 709-715
Prostate artery chemoembolization in prostate cancer: A proof of concept study in spontaneous prostate cancer in a canine model
- 1 August 2021
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 32 (8) , 1136-1143
Safety and Efficacy of Peripheral Embolization with EASYX Liquid Embolic Agent: A Multicenter Prospective Study
- 1 August 2021
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 32 (8) , 1136-1143
Safety and Efficacy of Peripheral Embolization with EASYX Liquid Embolic Agent: A Multicenter Prospective Study
- 1 March 2021
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 102 (3) , 141-145
Association between intravesical prostatic protrusion and clinical outcomes in prostatic artery embolization
- 1 March 2021
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 102 (3) , 141-145
Association between intravesical prostatic protrusion and clinical outcomes in prostatic artery embolization